Lv51
1210 积分 2022-08-16 加入
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature
2小时前
待确认
Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core—an adaptive measure of core quality of life domains in oncology clinical practice and research
6天前
已完结
1482 In-vivoCAR-T cells produced by specific virus in refractory B cell lymphoma
1个月前
已完结
Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
2个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
3个月前
已完结
从临床数据解释细胞色素P-450抑制和诱导作用：当前标准和实施建议
8个月前
已完结
Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies
8个月前
已关闭
Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies
8个月前
已关闭
Scientific and Regulatory Policy Committee
8个月前
已完结
Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
8个月前
已完结
皖公网安备34019202002308
